Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study
Diabetes Research and Clinical Practice, 3, 98, pages 408 - 413
Published online Dec-2012
The A1chieve® study was funded by Novo Nordisk.
© 2012 Elsevier Ireland Ltd, All rights reserved.